A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer.

Autor:	Woo XY; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Srivastava A; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Mack PC; University of California Davis Comprehensive Cancer Center, Sacramento, California., Graber JH; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Sanderson BJ; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Lloyd MW; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Chen M; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Domanskyi S; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Gandour-Edwards R; University of California Davis Comprehensive Cancer Center, Sacramento, California., Tsai RA; University of California Davis Comprehensive Cancer Center, Sacramento, California., Keck J; The Jackson Laboratory, Sacramento, California., Cheng M; The Jackson Laboratory, Sacramento, California., Bundy M; The Jackson Laboratory, Sacramento, California., Jocoy EL; The Jackson Laboratory, Sacramento, California., Riess JW; University of California Davis Comprehensive Cancer Center, Sacramento, California., Holland W; University of California Davis Comprehensive Cancer Center, Sacramento, California., Grubb SC; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Peterson JG; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Stafford GA; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Paisie C; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Neuhauser SB; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Karuturi RKM; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., George J; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Simons AK; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Chavaree M; University of California Davis Comprehensive Cancer Center, Sacramento, California.; Eastern Maine Medical Center, Lafayette Family Cancer Center, Brewer, Maine., Tepper CG; University of California Davis Comprehensive Cancer Center, Sacramento, California., Goodwin N; The Jackson Laboratory, Sacramento, California., Airhart SD; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Lara PN; University of California Davis Comprehensive Cancer Center, Sacramento, California., Openshaw TH; Eastern Maine Medical Center, Lafayette Family Cancer Center, Brewer, Maine., Liu ET; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine., Gandara DR; University of California Davis Comprehensive Cancer Center, Sacramento, California., Bult CJ; The Jackson Laboratory for Mammalian Genetics, Bar Harbor, Maine.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2022 Nov 15; Vol. 82 (22), pp. 4126-4138.
DOI:	10.1158/0008-5472.CAN-22-0948
Abstrakt:	Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung cancer PDXs available from The Jackson Laboratory that have been extensively characterized for histopathologic features, mutational profiles, gene expression, and copy-number aberrations. Most of the PDXs are models of non-small cell lung cancer (NSCLC), including 37 lung adenocarcinoma (LUAD) and 33 lung squamous cell carcinoma (LUSC) models. Other lung cancer models in the repository include four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenosquamous carcinomas, and one pleomorphic carcinoma. Models with both de novo and acquired resistance to targeted therapies with tyrosine kinase inhibitors are available in the collection. The genomic profiles of the LUAD and LUSC PDX models are consistent with those observed in patient tumors from The Cancer Genome Atlas and previously characterized gene expression-based molecular subtypes. Clinically relevant mutations identified in the original patient tumors were confirmed in engrafted PDX tumors. Treatment studies performed in a subset of the models recapitulated the responses expected on the basis of the observed genomic profiles. These models therefore serve as a valuable preclinical platform for translational cancer research. Significance: Patient-derived xenografts of lung cancer retain key features observed in the originating patient tumors and show expected responses to treatment with standard-of-care agents, providing experimentally tractable and reproducible models for preclinical investigations. (©2022 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu